The global precocious puberty treatment market is expected to witness significant growth over the next decade, with a valuation of US$ 1,716.43 million in 2023, and projected to reach US$ 3,650.66 million by 2033. According to industry reports, the market is anticipated to grow at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2023 to 2033.
Precocious puberty, a condition where puberty begins unusually early in children, has seen rising incidence in recent years, prompting the need for effective treatment options. The growth of this market is fueled by increased research and development efforts by key players to develop novel drugs, as well as the expansion of indication labels for existing medications.
Key Market Drivers:
- Advancements in Drug Development: Leading pharmaceutical companies are increasingly focused on developing new and innovative drugs for the treatment of precocious puberty. Ongoing research aimed at improving patient outcomes is a key factor driving market expansion.
- Expansion of Indication Labels: The extension of indication labels for already available treatments is expected to enhance the availability of effective solutions, further supporting market growth.
- Rising Awareness and Diagnosis: Greater awareness of precocious puberty and its potential long-term health impacts, coupled with improvements in early diagnosis, are driving demand for effective treatments across global markets.
Regional Outlook: North America is expected to dominate the global precocious puberty treatment market due to strong healthcare infrastructure, significant investment in research and development, and a growing focus on pediatric health. Europe is also projected to hold a substantial market share, while the Asia-Pacific region is emerging as a key market due to increased healthcare access and rising awareness of the condition in countries such as China and India.
Future Outlook: As pharmaceutical companies continue to advance drug development for the treatment of precocious puberty, the market is set to experience sustained growth. With rising awareness of early puberty and the availability of more effective treatments, the global market for precocious puberty treatment is expected to see continued expansion through 2033.
Likewise, these players are focusing on a number of inorganic strategies such as partnerships, mergers, and agreements, which is expected to drive the precocious puberty market growth during the forecast period. For example, in January 2016, Debiopharm International SA (Debiopharm) which is a part of Debiopharm Group, made an agreement for exclusive distribution agreement with Arbor Pharmaceuticals, a pharmaceutical company, for the commercialization and promotion of triptorelin 22.5 mg for Central precocious puberty treatment.
On the other hand, surging research and development activities in triptorelin for applications in several therapeutic indications, by private manufacturers and research organizations is fuelling growth of precocious puberty treatment market. Moreover, the higher efficacy and tolerability of triptorelin in the suppression of gonadotropin secretion in prostate cancer and precocious puberty is surging the adoption of triptorelin in the market which is anticipated to benefit the market of precocious puberty.
Also, the engagement by key players in expanding their product portfolio in several geographical areas is expected to aid market growth. For example, in October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA commercialized availability of Triptodur (triptorelin), in the United States for the treatment of pediatric patients two years and older diagnosed with Precocious Puberty. Furthermore, reimbursement for the treatment of precocious puberty is provided through Medicaid, which is estimated to offer lucrative growth prospects for the global precocious puberty market during the forecast period.
Key Takeaways:
- North America is expected to dominate the industry while reaching market share of around 46.7% by end of the forecast period.
- The market in East Asia is projected to account for 25% market share by end of the projected period.
- By drug class, ‘triptorelin’ is projected to account for 62% market share by end of the forecast period.
- Hospitals are expected to dominate the market by distribution channel, with a market share of 58% by 2033.
“Increasing rate of product approvals, surging growth in mergers and acquisitions between companies, and development of new drugs will increase the product demand for treatment of precocious puberty,” comments an FMI analyst.
Market Competition
The precocious puberty treatment market is extremely competitive and consists of various key market players. These players are developing novel delivery systems for treating precocious puberty. This is anticipated to fuel precocious puberty treatment market. The key players in this market are: Teva Pharmaceutical Industries Ltd, AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc, Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, Sun Pharmaceutical Industries Limited, and Sanofi S.A.
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, partnerships, and collaboration in order to bolster their product portfolio. This is expected to propel the global precocious puberty treatment market.
- In June, 2020, Ipsen Pharma underwent strategic partnership with Debiopharm for Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for treating central precocious puberty in children. This strategic merger helped the company to maintain a continuous product access to patients.
- In March 2022, Accord BioPharma, the United States special division of Intas Pharmaceuticals, Ltd. declared the United States launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of progressive prostate cancer in adults.
- In February 2022, BDR Pharmaceuticals revealed its brand ENZALUTAMIDE, an antiandrogen in 160mg with brand name BDENZA for treatment of Prostate Cancer patients.
- In January 2019, Debiopharm Group informed about an agreement with Allergan to begin a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the United States and Canada and the termination of Allergan’s partnership with Debiopharm for strategic reasons.
Key Companies Profiled
- Teva Pharmaceutical Industries Ltd
- AbbVie Inc.
- Arbor Pharmaceuticals, LLC
- Pfizer Inc.
- Tolmar Pharmaceuticals, Inc.
- Endo International Plc.
- Ipsen Pharma
- Debiopharm Group
- Sun Pharmaceutical Industries Limited
- Sanofi S.A
Key Segments Profiled in the Precocious Puberty Treatment Industry Survey
By Drug Class:
- Leuprorelin
- Histrein
- Triptorelin
- Nafarelin
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube